Takeda Pharmaceutical and Ovid Therapeutics announced that the companies have gathered positive data from their Phase II ELEKTRA study of soticlestat in children with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS).
https://www.pharmalive.com/wp-content/uploads/2020/08/Takeda-and-Ovid’s-Epilepsy-Drug-Sees-Positive-Results-in-Phase-II-Trial-BioSpace-8-26-20.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2020-08-26 15:06:182020-08-26 15:06:18Takeda and Ovid’s Epilepsy Drug Sees Positive Results in Phase II Trial